Related Experiment Video
Updated: Nov 2, 2025

12:40
Cultivation of Heligmosomoides Polygyrus: An Immunomodulatory Nematode Parasite and its Secreted Products
Published on: April 6, 2015
18.8K
Hookworm treatment induces a decrease of suppressive regulatory T cell associated with a Th2 inflammatory response.
Virginie Doyen1,2, Francis Corazza1,3, Hoa Nhu Thi4
1Laboratory of Translational Research, ULB223, CHU Brugmann, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Plos One
|June 10, 2021
Summary
Hookworm infection increases regulatory T cells (Treg), including suppressive and non-suppressive types. Treatment reduces these Treg cells and triggers a Th2 inflammatory response.
Area of Science:
- Immunology
- Parasitology
- Infectious Diseases
Background:
- Helminth infections, like hookworm (HW), modulate host immune responses.
- Limited data exists on immune response evolution post-treatment for hookworm infections.
Purpose of the Study:
- To phenotype the regulatory immune response during natural hookworm infection.
- To track the immune response evolution after antiparasitic treatment.
Main Methods:
- Blood and fecal samples collected from hookworm-infected (HW+) and non-infected (HW-) individuals.
- Analysis of hematological parameters, regulatory T cells (Treg), surface molecules, and cytokines before and after Albendazole treatment.
- Longitudinal sampling up to 12 months post-treatment in the HW+ group.
Main Results:
- HW+ subjects exhibited increased Treg, including suppressive (TregICOS+, Treg PD1-, rTreg) and non-suppressive phenotypes.
- No significant difference in Th1/Th2 orientation or IL-10 levels between groups.
- Post-treatment, Treg populations decreased, accompanied by increased IL-4 and IL-6 cytokine levels.
Conclusions:
- Hookworm infection leads to a heterogeneous increase in regulatory T cells.
- Treatment-induced reduction in suppressive Treg phenotypes correlates with a developing Th2 inflammatory response.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
299
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
299
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
272
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
272

